Reviews/Perioperative Immunotherapy Solid Tumours/KEYNOTE-522 pathological complete response and event-free survival in triple-negative breast cancer
Tnbc · PERIO-TNBC-01 · v2
A large phase 3 trial tested adding pembrolizumab, an immunotherapy drug, to chemotherapy before surgery and then continuing it after surgery in women with early triple-negative breast cancer. More patients had no detectable cancer left at surgery (64.8% vs 51.2%) [13] and fewer went on to have their cancer return or progress [12], and longer follow-up later showed patients also lived longer [14]. Several real-world hospital studies treating patients the same way saw similar results, including one that compared against patients not given the drug [18][7]. The main caveats are that all the randomized evidence comes from this one trial, and the trial cannot tell us how much the post-surgery doses specifically contributed [10]. Even so, the regimen as a whole does what the claim says for both response at surgery and keeping the cancer from coming back.
The pivotal phase 3 trial carries both halves of the claim directly: pathological complete response of 64.8% versus 51.2% [13] and 36-month event-free survival of 84.5% versus 76.8% with a hazard ratio of 0.63 [12]. Durability holds to ~5 years at a median 63.1-month follow-up with the same hazard ratio of 0.63 [5], and overall survival at 60 months reached 86.6% versus 81.7% (P = 0.002) [14]. The effect is concordant in the Japan subgroup, where 60-month event-free survival was 84% versus 73% [9], and an exploratory residual-cancer-burden analysis shows the event-free survival gain extends beyond patients achieving pathological complete response [11]. Independent real-world cohorts corroborate, including a comparative cohort with pathological complete response of 59.3% versus 33.1% [18] and a cohort mirroring the trial at 63.9% with 2-year event-free survival of 87.2% [7]. The contested point: The division is over evidential independence rather than effect: every randomized data point is the same trial ([5][6][9][11][12][13][14]), so corroboration beyond it comes only from uncontrolled cohorts. The regimen also bundles the neoadjuvant and adjuvant phases, so the specific contribution of adjuvant pembrolizumab cannot be isolated, a question [10] explicitly flags.
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All randomized evidence for the claim derives from a single trial (KEYNOTE-522 / NCT03036488): [5], [6], [9], [11], [12], [13], [14] are the same study. There is no independent confirmatory RCT in the corpus; corroboration beyond it is only from uncontrolled real-world cohorts.
The regimen bundles neoadjuvant and adjuvant pembrolizumab, and the trial cannot isolate the adjuvant phase's contribution to the EFS benefit; [10] explicitly flags the unresolved question of 'incremental benefit from adjuvant pembrolizumab beyond the neoadjuvant component.' The claim as worded (the whole regimen) is supported, but any implication that the adjuvant component is independently proven is not.
Where it remains uncertain. All randomized evidence is a single trial [12][13][14] and the adjuvant phase's own contribution cannot be separated from the neoadjuvant phase [10].
Aleatory
The Japan subgroup (N=76) gives a wide event-free survival confidence interval (HR 0.54; 95% CI 0.20-1.50) [9], and real-world cohorts record few recurrence or death events [7][10], so random variation is large.
Epistemic
All randomized evidence is KEYNOTE-522 [5][6][9][11][12][13][14]; no independent confirmatory RCT exists in the corpus, so true replication of the randomized effect is unknown.
Inferential
Single-arm cohorts [7][10] report pCR rates without a concurrent comparator, so they cannot by themselves establish 'improves' versus chemotherapy alone.
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Demonstrates durability of the EFS benefit at ~5-year follow-up.
“145 pts (18.5%) in the pembro group and 108 pts (27.7%) in the pbo group had an EFS event (hazard ratio [HR] 0.63 [95% CI, 0.49-0.81])”
Panel auditInternal validity: high · scope of inference: Early-stage TNBC (T1c N1-2 or T2-4 N0-2) receiving the KEYNOTE-522 regimen.Key limitations: conference abstract · OS follow-up ongoing
Real-world confirmation of pCR and favourable EFS consistent with trial results.
“The observed pCR rate was 63.9%, closely mirroring the 64.8% reported in the KEYNOTE-522 trial. At the two-year mark, the EFS rate was 87.2% and the OS rate was 92.3%.”
Panel auditInternal validity: low · scope of inference: Real-world efficacy/safety of neoadjuvant pembro-chemo in Turkish early TNBC patients.Key limitations: retrospective · no comparator · heterogeneous regimens
Trial subgroup showing directionally concordant EFS benefit.
“Rates of EFS at 60 months were 84% and 73%, respectively (HR, 0.54; 95% CI, 0.20-1.50)”
Panel auditInternal validity: medium · scope of inference: Japanese high-risk early TNBC subgroup of KEYNOTE-522.Key limitations: small underpowered subgroup · wide confidence intervals
This is a study-design abstract; no outcome data are reported.
Panel auditInternal validity: not assessable from abstract · scope of inference: Planned phase 3 evaluation of the regimen in previously untreated nonmetastatic TNBC.Key limitations: no results · trial-in-progress
4 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Both claimed effects are definitively demonstrated in the practice-changing pivotal RCT and replicated across real-world data, warranting Established tier just short of ceiling given the single-trial randomized foundation.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adjuvant component not isolated. The regimen bundles both phases, so the incremental benefit of adjuvant pembrolizumab beyond the neoadjuvant component is unknown [10]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomized trial of adjuvant pembrolizumab versus observation after neoadjuvant pembrolizumab plus chemotherapy, such as the de-escalation design in [15].
Open question: Does adjuvant pembrolizumab add benefit beyond the neoadjuvant phase, particularly in patients who achieve pCR? Why it is still open: The trial cannot decompose the bundled regimen and [10] explicitly flags the unresolved incremental-benefit question; [15] is a design with no results.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19